ReviewEndocrine2012
Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy.
Review in Endocrine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 47 citations in OpenAlex.
- The erythropoietin gene polymorphism (rs1617640) is associated with retinopathy in type 2 diabetes patients.Acta diabetologica · 2026Article
- Exploring systemic erythropoietin in diabetic retinopathy: Longitudinal associations and biomarker potential in the LANDMark cohort.PloS one · 2026Article
- Article
- Integrated Assessment of OCT, Multimodal Imaging, and Cytokine Markers for Predicting Treatment Responses in Retinal Vein Occlusion Associated Macular Edema: A Comparative Review of Anti-VEGF and Steroid Therapies.Diagnostics (Basel, Switzerland) · 2024Review
- Evaluation of Hypoxia and Microcirculation Factors in the Progression of Diabetic Retinopathy.Investigative ophthalmology & visual science · 2024Article
- Systemic Cytokines in Retinopathy of Prematurity.Journal of personalized medicine · 2023Review
- Relevance of Peptide Homeostasis in Metabolic Retinal Degenerative Disorders: Curative Potential in Genetically Modified Mice.Frontiers in pharmacology · 2021Review
- A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.Journal of clinical medicine · 2020Article
- Serum erythropoietin concentration and its correlation with stage of diabetic retinopathy.BMC ophthalmology · 2019Article
- Carbamazepine Alleviates Retinal and Optic Nerve Neural Degeneration in Diabetic Mice via Nerve Growth Factor-Induced PI3K/Akt/mTOR Activation.Frontiers in neuroscience · 2019Article
- Sweet Stress: Coping With Vascular Dysfunction in Diabetic Retinopathy.Frontiers in physiology · 2018Review
- Revisiting the role of erythropoietin for treatment of ocular disorders.Eye (London, England) · 2016Review
- Epo inhibits the fibrosis and migration of Müller glial cells induced by TGF-β and high glucose.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2016Article
- Involvement of Renin-Angiotensin System in Retinopathy of Prematurity - A Possible Target for Therapeutic Intervention.PloS one · 2016Article
- Systemic treatment with erythropoietin protects the neurovascular unit in a rat model of retinal neurodegeneration.PloS one · 2014Article
- Aqueous levels of erythropoietin in acute retinal vein occlusion with macular edema.International journal of ophthalmology · 2014Article
- Diabetic Retinopathy-Update on Prevention Techniques, Present Therapies, and New Leads.US ophthalmic review · 2014Article
- Genetics in diabetic retinopathy: current concepts and new insights.Current genomics · 2013Article
- Neuropeptides and diabetic retinopathy.British journal of clinical pharmacology · 2013Review
- Novel targets against retinal angiogenesis in diabetic retinopathy.Current diabetes reports · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoietin (Epo) is the principal regulator of erythropoiesis by inhibiting apoptosis and by stimulating the proliferation and differentiation of erythroid precursor cells. However, Epo also performs extra-erythropoietic actions of which the neuroprotective effects are among the most relevant. Apart from kidney and liver, Epo is also produced by the brain and the retina. In addition, Epo receptor (Epo-R) expression has also been found in the brain and in the retina, thus suggesting an autocrine/paracrine action which seems essential for the physiological homeostasis of both brain and retina. In this review, we will give an overview of the current concepts of the physiology of Epo and will focus on its role in the retina in both normal conditions and in the setting of diabetic retinopathy. Finally, the reasons as to why Epo could be contemplated as a potential new treatment for the early stages of diabetic retinopathy will be given.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.